Beyond Air Inc

Beyond Air, Inc. explores nitric‑oxide therapies for respiratory disease but faces volatile stock and negative earnings—high‑risk but potentially breakthrough.

Beyond Air’s $32 M NeuroNOS sale sparks a 165 % stock spike, funding its respiratory focus while eyeing lucrative autism therapy—an enticing, volatile biotech play.

Beyond Air, Inc. is a medical device and biopharmaceutical company focused on developing nitric oxide formulations and delivery systems to transform the treatment landscape for respiratory conditions.

Beyond Air Inc. is a medical device and biopharmaceutical company pioneering the use of nitric oxide to revolutionize respiratory health care and improve patient outcomes.

Beyond Air Inc. is a struggling biopharmaceutical company facing significant financial challenges despite its innovative approach to treating respiratory diseases.

Beyond Air Inc. is a struggling biopharmaceutical company facing significant financial challenges despite its innovative approach to treating respiratory diseases.